Bristol-Myers Squibb is a company in transition, with a host of new products under regulatory review or in clinical development. Here are three reasons why the company may falter in its plan to move past the patent cliff.
Bristol-Myers Squibb is a company in transition, with a host of new products under regulatory review or in clinical development. Here are three reasons why the company may falter in its plan to move past the patent cliff.